

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

ADVANCED MEDICAL TECHNOLOGY ASSN

2. Address:

1200 G ST NW #400, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: MEGAN M. IVORY

Telephone: 202-783-8700

E-mail (optional): mivory@advamed.org

Senate ID #: 17831-12

House ID #: 31001000

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 2,460,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☒ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ADVANCED MEDICAL TECHNOLOGY ASSN Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 2744-Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006. (Bill making appropriations for the fiscal year ending September 30, 2006.)

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CHILDS, BLAIR

Covered Official Position (if applicable): N/A

Name: IVORY, MEGAN

Covered Official Position (if applicable): N/A

Name: KELLY, CAROL

Covered Official Position (if applicable): N/A

Name: NEXON, DAVID

Covered Official Position (if applicable): N/A

Name: RADUS, SETH

Covered Official Position (if applicable): N/A

Name: TRUNZO, JANET

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R.3423/S.1420-Medical Device User Fee Stabilization Act of 2005. (Bills related to user fees for medical devices.) H.R. 2090-Food and Drug Administration Improvement Act of 2005 (Bill related to FDA Advisory panels.) H.R.3196/S.470-Fair Access to Clinical Trials (FACT) Act (Bills to expand the scope of information required for the data bank on clinical trials.) S.3-Protecting America in the War on Terror Act of 2005 - Biopreparedness Act of 2005. (Bill sets provisions concerning bioterrorism preparedness and defense as pertaining to medical devices.) S.975-The Project Bioshield II Act of 2005. (Bill to provide incentives to increase research by private sector entities to develop medical countermeasures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak.) H.R.5-Help, Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2005. (Bill to provide improved medical care by reducing excessive burden the liability system places on the health care delivery system.) S.295-To authorize appropriate action if the negotiations with the People's Republic of China's undervalued currency are not successful. (Bill to impose an additional duty of 27.5% on Chinese imports.) H.R.3004-Currency Harmonization Initiative through Neutralizing Action Act of 2005. (Bill to impose additional tariffs on Chinese imports on the basis of the rate of manipulation by that country of the rate of exchange between the Chinese currency and the U.S. dollar.) H.R.3045/S.1307-Dominican Republic-Central American-United States Free Trade Agreement Implementation Act. (Bills implementing the Central American-Dominican Republic Free Trade Agreement (CAFTA-DR) into law.) H.R.3283/S.1421-United States Trade Rights Amendments Act (Bill to enhance resources to enforce U.S. trade rights.) S.950-Elimination of Neglected Diseases Act of 2005. (Bill to provide assistance to combat tuberculosis, malaria and other infectious diseases.) S.1223-Information Technology for Health Care Quality and Improvement Act. S.1355-Better Healthcare Through Information Technoogy. (Bills to enhance the adoption of health information technology and to improve the quality and reduce the costs of health care in the United States.) S.1262-Health Technology to Enhance Quality Act of 2005. S.1418-Wired for Health Care Quality Act (Bills to reduce healthcare costs, improve efficiency and healthcare quality through development of a nation-wide interoperable health information technology system.) S.978-Healthcare Tax Relief for the Uninsured Act of 2005. H.R.1872-Health Coverage for the Uninsured Act of 2005. (Bills to provide tax incentives for the purchase of quality health care, and for other purposes.)

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Office of Management & Budget (OMB)
SENATE
U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: FEDERICI, TARA M.
Covered Official Position (if applicable): N/A
Name: FOOTE, JAN
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: NEXON, DAVID
Covered Official Position (if applicable): N/A
Name: RADUS, SETH
Covered Official Position (if applicable): N/A
Name: THORPE, JANE
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ADVANCED MEDICAL TECHNOLOGY ASSN Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S.1002-Hospital Fair Competition Act of 2005. (Bill to make improvements in payments to hospitals under the Medicare program.)
S.1356-Medicare Value Purchasing Act of 2005. (Bill to provide incentives for the provision of high quality care under the Medicare program.) H.R.3617-Medicare Value-Based Purchasing for Physicians' Services Act of 2005. (Bill to provide for value-based purchasing in the payment for physicians' services under the Medicare program.)

17. House(s) of Congress and Federal agencies contacted:
Centers For Medicare and Medicaid Services (CMS)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: GATEWOOD, JOSEPH
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: LEE, TERESA
Covered Official Position (if applicable): N/A
Name: NEXON, DAVID
Covered Official Position (if applicable): N/A
Name: RADUS, SETH
Covered Official Position (if applicable): N/A
Name: THORPE, JANE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 11, 2005

Printed Name and Title: MEGAN M. IVORY - EXECUTIVE VICE PRESIDENT, FEDERAL GOVERNMENT RELAT

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: BAILEY, PAM

Name: CLARY, MELISSA

Name: KELLY, CAROL

Name: MCBRIDE, VERONICA

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 12, 2005

Printed Name and Title: MEGAN M. IVORY - EXECUTIVE VICE PRESIDENT, FEDERAL GOVERNMENT RELAT